Are physician recommendations for <i>BRCA1/2</i> testing in patients with breast cancer appropriate? A population‐based study
Anne Marie McCarthy(Massachusetts General Hospital), Katrina Armstrong(Columbia University), Judy A. Shea(University of Pennsylvania), Susan M. Domchek(University City Science Center), Irene Roelfsema(University of Pennsylvania), Tracey Fredricks(University of Pennsylvania), Mirar N. Bristol(Harvard University), Peter W. Groeneveld(Harvard University), Kaijun Liao, Lache Wilkins(United States Department of Veterans Affairs)
Cited by 25
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981